ENLV Enlivex Therapeutics Ltd.
Healthcare$0.72-0.37%ClosedMarket Cap: $17.4M
As of 2026-05-25
Valuation
View DetailsP/E (TTM)
0.02
PEG
0.00
P/B
0.02
P/S
0.00
EV/EBITDA
-1.12
DCF Value
$-0.04
FCF Yield
-63.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
248.1%
ROA
53.1%
ROIC
-0.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 null | $0.00 | $1.24B | $— |
| FY null | $0.00 | $1.24B | $— |
| Q3 null | $0.00 | $-2.2M | $— |
| Q2 null | $0.00 | $-1.9M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$15.00
Target (Median)
$15.00
Target Range
$15.00 - $15.00
0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2026-04-07HC Wainwright & Co.Buy
2026-01-12D. Boral CapitalHold
2025-11-24D. Boral CapitalBuy
2025-10-29D. Boral CapitalBuy
2025-09-26Trading Activity
Insider Trades
View AllShlosberger Shacharofficer: Chief Financial Officer
SellWed Mar 18
Shlosberger Shacharofficer: Chief Financial Officer
SellWed Mar 18
Shlosberger Shacharofficer: Chief Financial Officer
SellWed Mar 18
Shlosberger Shacharofficer: Chief Financial Officer
SellWed Mar 18
Shlosberger Shacharofficer: Chief Financial Officer
SellWed Mar 18
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
IL
Exchange
—
Beta
1.49
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.